The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Patients currently seeking buprenorphine treatment (Last 30 Days)

Click here for advanced timeframe map.
Focus on your zip code:
0 patients seeking buprenorphine treatment in the last 30 days.
Generate your IRS tax receipt:
Enter the information below then hit Submit. We'd appreciate comments on the PSA play rotation.
            
   
Each marker represents a zip code location with at least one patient registered on the NAABT Patient/Physician Matching System.
Request a new CD for your radio station
(all requested information is required):
CD Jacket for NAABT 2010 PSA
First Name:
Last Name:
Station/Call Letters:
Street Address:
City:
State:
Zip Code:
Listen to the TreatmentMatch PSAs (MP3 format):
  1. Do you know how to help (30 seconds)
  2. Just quitting isn’t enough (60 seconds)
  3. Someone in your life (15 seconds)
Download set of PSAs (.zip file):
  1. :15, :30 & :60 PSA (WAV format)
  2. :15, :30 & :60 PSA (AIFF format)
This page was last modified on : 11/21/2013

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release